-
Recent Posts
- Board IPR FWD finding Sanofi’s amended claims not unpatentable affirmed
- DC grant of SJ to SIMO reversed without remand due to improper construction of preamble
- “Substantial risk of future infringement” provides standing for IPR appeal; non-obviousness conclusion vacated and remanded
- DC grant of SJ of infringement to Lilly under DOE affirmed
- FC panel affirmed DC claim construction based in part on Maia’s stipulation to infringement
Recent Comments
Categories
- America Invents Act
- Analgous Art
- Anticipation (35 USC 102)
- Antitrust
- Appeal
- Arbitration
- Article III disputes
- Assignment / Ownership
- Attorney's Fees
- Bankruptcy
- Best mode
- Biosimilars
- Business methods
- Certificate of Correction
- Claim
- Claim Construction
- Claim Differentiation
- Claim Preclusion
- Claim Vitiation
- Collateral estoppel
- comprising
- Conception and Reduction to Practice
- consisting of
- Contributory Infringement
- Copyright
- Covered Business Method Reviews
- Damages
- Derivation of Invention
- Design Patents
- Diligence
- Disclaimers
- Discovery
- Doctrine of equivalents
- Double Patenting
- Enablement
- Equitable estoppel
- Exhaustion and Repair
- Experimental Use
- Expert Testimony
- Extension (156)
- False Marking
- Functional limitations
- Generics / ANDA
- Importation
- Indefiniteness
- Inducement to Infringe
- Inequitable Conduct
- Infringement
- Inherency
- Injunction
- Inter Parties Review (IPR)
- Interference
- International Trade Commission
- Inventorship
- IPR
- Issue Preclusion
- Jurisdiction
- Laches
- Licensing
- Lost Profits
- Malpractice
- Means-plus-function
- Method claims
- Negative Limitations
- Obviousness
- Obviousness (Secondary Considerations)
- Obviousness-Teaching Away
- On-Sale Bar
- Patent Eligibility (101)
- Patent Exhaustion
- Patent Marking
- Patent Prosecution
- Patent Term Adjustment (PTA)
- Patent Term Extension
- Patentability
- Post-grant review
- Preamble
- Priority
- Privilege
- Procedural Issues
- Product-by-Process
- Prosecution History Estoppel
- Public Accessibility
- Public Use
- Reexamination
- Reissue
- Royalties
- Safe Harbor, FDA exemptions (271(e)(1))
- Section 101 (see also Patentability)
- Software
- State Sovereignty
- Summary Judgment
- Terminal Disclaimers
- Trade Dress
- Trade Secret
- Trademarks
- U.S. Supreme Court
- Uncategorized
- Unenforceability
- Unjust enrichment
- Utility
- Venue
- Wherein
- Willfullness
- Written description
Archives
- January 2021
- December 2020
- November 2020
- October 2020
- September 2020
- August 2020
- July 2020
- June 2020
- May 2020
- April 2020
- March 2020
- February 2020
- January 2020
- December 2019
- November 2019
- October 2019
- September 2019
- August 2019
- July 2019
- June 2019
- May 2019
- April 2019
- March 2019
- February 2019
- January 2019
- December 2018
- November 2018
- October 2018
- September 2018
- August 2018
- July 2018
- June 2018
- May 2018
- April 2018
- March 2018
- February 2018
- January 2018
- December 2017
- November 2017
- October 2017
- September 2017
- August 2017
- July 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- October 2016
- September 2016
- August 2016
- July 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- November 2015
- October 2015
- September 2015
- August 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- July 2011
- February 2011
- January 2011
Meta
- Anticipation (35 USC 102) Appeal Article III disputes Assignment / Ownership Attorney's Fees Claim Construction Claim Differentiation Collateral estoppel Damages Doctrine of equivalents Generics / ANDA Indefiniteness Inducement to Infringe Infringement Injunction Inter Parties Review (IPR) Inventorship IPR Licensing Means-plus-function Obviousness Obviousness-Teaching Away Patentability Prosecution History Estoppel Reexamination Software Trademarks Uncategorized Willfullness Written description
Copyright Notice
© Patrick J. Halloran, Ph.D., J.D. and lifescienceip.wordpress.com, [2011-2017]. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Patrick J. Halloran, Ph.D., J.D. and lifescienceip.wordpress.com with appropriate and specific direction to the original content.
Category Archives: Conception and Reduction to Practice
DC decision adding Dana Farber/GI (Pfizer) inventors to Ono/BMS anti-PD1 patents affirmed
Dana-Farber Cancer Institute, Inc. v. Ono Pharm. Co., et al. (Bristol-Myers Squibb) Docket No. 2019-2050 NEWMAN, LOURIE, STOLL July 14, 2020 Brief Summary: DC order to add Dana Farber and GI/Pfizer inventors to the Ono/BMS relating to the use of … Continue reading
Federal Circuit affirms Board IPR decision invalidating design patents for obviousness
Kolcraft Enterprises, Inc. v. Graco Children’s Products, Inc. Docket No. 2018-1259-60 (IPR2016-00816, -00826) MOORE, REYNA, CHEN July 2, 2019 Brief summary: Board IPR decision of invalidity of Kolcraft’s design patents affirmed as evidence regarding inventor’s date of conception was uncorroborated. … Continue reading
Federal Circuit affirmed DC claim construction finding that “100% by weight” limitation can include “residual moisture”
E.I. Du Pont De Nemours & Co. v. Unifrax I LLC Docket 2017-2575 O’MALLEY, REYNA, HUGHES April 17, 2019 Brief summary: DC finding that “platelets in an amount of 100% by weight” can include “some residual dispersant” and its denial … Continue reading
ATI Technologies ULC v. Andrei Iancu (USPTO)
Docket No. 2016-2222, -2406, -2608 (IPR2015-00325, -00326, -00330) NEWMAN, O’MALLEY, WALLACH April 11, 2019 Brief summary: PTAB finding of invalidity due to ATI’s lack of diligence before filing its patent applications reversed (e.g., “[t]he PTAB identified no delays” or “gaps … Continue reading
Mark A. Barry v. Medtronic, Inc.
Docket No. 2017-2463 PROST, MOORE, TARANTO January 24, 2019 Brief summary: DC and jury conclusions of no invalidity and infringement affirmed (e.g., the invention was not in “public use” as the use was experimental, no § 102(b) on-sale bar, no … Continue reading
Apator Miitors APS v. Kamstrup A/S
Docket No. 2017-1681 (IPR2015-01403) MOORE, LINN, CHEN April 17, 2018 Brief summary: PTAB IPR final written decision (FWD) finding anticipation and obviousness, and rejected Apator’s proffered evidence of prior conception since it was based only on the inventor’s own statements … Continue reading
Raytheon Company v. Sony Corporation, Samsung Electronics Co., Ltd. et al.
Docket Nos. 2017-1554, -1556, -1557 (IPR2015-01201; IPR2016-00209, -00962) LOURIE, O’MALLEY, TARANTO April 2, 2018 Non-precedential Brief summary: Board’s obviousness determination following IPR affirmed because, e.g., Raytheon did “not explain why the resulting device” (of the prior) “would be rendered inoperable … Continue reading
Nintendo of America Inc. et al. v. iLife Technologies, Inc.
Docket Nos. 2016-2266 (IPR2015-00109) LOURIE, TARANTO, CHEN December 27, 2017 Non-precedential Brief summary: The FC panel affirmed the PTAB’s decision of reduction to practice before the prior art date for certain claims but reversed as to others (e.g., “prototype has … Continue reading
Art+Com InnovationPool GmbH v. Google LLC
Docket Nos. 2017-1016 LOURIE, O’MALLEY, TARANTO October 20, 2017 Non-precedential Brief summary: DC entry of jury anticipation finding affirmed; finding of no infringement by Google was not reached by the FC panel. Summary: Art+Com (“AC”) appealed DC entry of judgment … Continue reading
NFC Technology, LLC v. Joseph Matal (USPTO)
Docket No. 2016-1808 (IPR2014-01198) LOURIE, REYNA, STOLL September 20, 2017 Brief summary: PTAB IPR FWD of invalidity for obviousness reversed and remanded as sufficient evidence corroborated inventor’s testimony regarding conception, and it must decide whether a prototype embodied the claimed … Continue reading